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Background: Transcranial electrical stimulation is a promising technique to facilitate behavioural improvements in
neurological and psychiatric populations. Recently there has been interest in remote delivery of stimulation within a
participant’s home.
Objective: The purpose of this review is to identify strategies employed to implement and monitor in-home
stimulation and identify whether these approaches are associated with protocol adherence, adverse events and
patient perspectives.
Methods: MEDLINE, Embase Classic + Embase, Emcare and PsycINFO databases and clinical trial registries were
searched to identify studies which reported primary data for any type of transcranial electrical stimulation applied
as a home-based treatment.
Results: Nineteen published studies from unique trials and ten on-going trials were included. For published data,
internal validity was assessed with the Cochrane risk of bias assessment tool with most studies exhibiting a high
level of bias possibly reflecting the preliminary nature of current work. Several different strategies were employed to
prepare the participant, deliver and monitor the in-home transcranial electrical stimulation. The use of real time
videoconferencing to monitor in-home transcranial electrical stimulation appeared to be associated with higher
levels of compliance with the stimulation protocol and greater participant satisfaction. There were no severe
adverse events associated with in-home stimulation.
Conclusions: Delivery of transcranial electrical stimulation within a person’s home offers many potential benefits
and appears acceptable and safe provided appropriate preparation and monitoring is provided. Future in-home
transcranial electrical stimulation studies should use real-time videoconferencing as one of the approaches to
facilitate delivery of this potentially beneficial treatment.
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Transcranial electrical stimulation (tES) is a technique
used to modulate cortical function and human behaviour.
It involves weak current passing through the scalp via sur-
face electrodes to stimulate the underlying brain. A com-
mon type of tES is transcranial direct current stimulation
(tDCS). Several studies have demonstrated tDCS is cap-
able of modulating cortical function, depending on the
direction of current flow [1–3]. When the anode is posi-
tioned over a cortical region, the current causes depolar-
isation of the neuronal cells, increasing spontaneous firing
rates [4]. Conversely, positioning the cathode over the tar-
get cortical region causes hyperpolarisation and a decrease
in spontaneous firing rates [4]. This modulation of cortical
activity can be observed beyond the period of stimulation
and is thought to be mediated by mechanisms which re-
semble long term potentiation and depression [5]. Along
similar lines, transcranial alternating current stimulation
(tACS) and transcranial random noise stimulation (tRNS)
are also forms of tES. Both tACS and tRNS are thought to
interact with ongoing oscillatory cortical rhythms in a fre-
quency dependent manner to influence human behaviour
[6–8].
The ability of tES to selectively modulate cortical ac-
tivity offers a promising tool to induce behavioural
change. Indeed, several studies have demonstrated that
tES may be a favourable approach to reduce impairment
following stroke [9], improve symptoms of neglect [10],
or reduce symptoms of depression [11]. While these re-
sults appear promising, there remains debate around
technical aspects of stimulation along with individual
participant characteristics that may influence the reli-
ability of a stimulation response [12–22]. However,
current evidence does suggest that effects of stimulation
may be cumulative, with greater behavioural improve-
ments observed following repeated stimulation sessions
[20]. Furthermore, tES has shown potential as a tool for
maintenance stimulation, with potential relapses of de-
pression managed by stimulation which continued over
several months [23, 24]. Therefore, it may be that re-
peated stimulation sessions will become a hallmark of
future clinical and research trials aiming to improve be-
havioural outcomes. This would require participants to
attend frequent treatment sessions applied over a num-
ber of days, months or years. Given that many partici-
pants who are likely to benefit from stimulation are
those with higher levels of motor or cognitive impair-
ment, the requirement to travel regularly for treatment
may present a barrier, limiting potential clinical utility or
ability to recruit suitable research participants [25]. In
addition, regular daily treatments would also hinder
those who travel from remote destinations to receive this
potentially beneficial neuromodulation. Therefore, there
is a requirement to consider approaches to safely andeffectively deliver stimulation away from the traditional
locations of research departments or clinical facilities.
One benefit of tES over other forms of non-invasive
brain stimulation, such as repetitive transcranial mag-
netic stimulation, is the ability to easily transport the re-
quired equipment. This opportunity may allow for
stimulation to be delivered in a participant’s home,
which could represent the mode of delivery for future
clinical applications. However, it may be unreasonable to
expect that a participant would be capable of managing
delivery of tES alone and would likely require some form
of training and/or monitoring [25]. Although tES is con-
sidered relatively safe [26], stimulation should be deliv-
ered within established guidelines to avoid adverse
events [27]. Inappropriate delivery of stimulation could
result in neural damage, detrimental behavioural effects,
irritation, burns or lesions of the skin [28–33]. There-
fore, in order to deliver stimulation safely to the appro-
priate cortical region, it is likely that in-home
stimulation may require some form of monitoring [25].
It is currently unclear what the best approach is to im-
plement and monitor in-home tES. An early paper pro-
posed several guidelines to perform in home tES [34].
However, these guidelines were not based on evidence
from published clinical trials as there were none avail-
able at the time of publication. One recent systematic re-
view sought to discuss current work in this area and
highlighted the need for further research to investigate
safety, technical monitoring and assessment of efficacy
[35]. Given the recent, and growing, interest in
home-based brain stimulation, we felt it was now pertin-
ent to conduct a review to specifically identify strategies
employed to implement and monitor the use of in-home
tES in neurological and psychiatric populations. The sec-
ondary questions were to report protocol adherence, ad-
verse events and patient perspectives of in-home tES.
Understanding optimal treatment fidelity for in-home
brain stimulation will be instrumental to achieving
higher levels of tES useability and acceptance within a
participant’s home.
Methods
This systematic review adhered to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines (Fig. 1) and is registered with the
International Prospective Register of Systematic Reviews
(PROSPERO Registration number CRD42018091960).
The literature search of studies that involve in-home tES
was performed in the following databases; MEDLINE
(1946 to February 2019), Embase Classic + Embase
(1947 to February 2019), Emcare (1995 to February
2019) and PsycINFO (1806 to February 2019). In
addition, trial registries (clinicaltrials.gov, anzctr.org.au
and who.int/ictrp/en/) were searched to identify current
Fig. 1 PRISMA flow diagram of study inclusion for this systematic review
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ruary 2019 using combinations of keywords relating to
in-home tES (search strategy available on PROSPERO,
CRD42018091960).
Studies were included if (i) they presented primary
data using any type of tES including tDCS, tRNS or
tACS as the treatment approach regardless of types of
montage as well as whether it was applied with or with-
out additional therapy (ii) the tES treatment was carried
out as a home-based treatment (iii) the study involved
humans of any age with neurological or psychiatric con-
ditions which included, but was not limited to, stroke,
Parkinson’s disease, traumatic brain injury and depres-
sion (iv) the study reported on compliance with treat-
ment protocol, adverse events or participant satisfaction
with home stimulation (v) the type of study was either a
randomised controlled trial, randomised cross-over trial,
observational study, case series, or qualitative study, and
(vi) the study was published or available in the English
language. All other studies that did not fulfil the inclu-
sion criteria were excluded.The review process was carried out in three steps.
First, one reviewer (N.S.) screened titles and abstracts
according to eligibility criteria and excluded studies
which were obviously not related to the search criteria.
Second, full text articles were retrieved and screened by
two reviewers (B.H. and N.S.) with a third reviewer
(S.H.) resolving any discrepancies that arose. The refer-
ence lists of included articles were then screened to
identify any additional articles that may not have been
found during the original search. Third, quality assess-
ment of each included study was carried out using the
Cochrane risk of bias assessment [36]. Two reviewers
(B.H. and N.S.) assessed bias individually and discrepan-
cies were resolved via discussion. The variables extracted
from the included papers were; (1) subject demographics
and clinical characteristics (age, gender, sample size,
clinical condition(s)), (2) details on strategies to facilitate
in-home tES treatment, (3) type of stimulator used, (4)
size and positioning of electrodes, (5) parameters of
stimulations for in-home sessions (current and dur-
ation), (6) monitoring approaches, (7) adverse events, (8)
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centage of correctly completed stimulation sessions rela-
tive to the total number of intended sessions, and (9)
perception of patients towards in-home tES treatment.
Where required, authors were contacted to obtain add-
itional data. Data were then synthesised using a narrative
approach to describe approaches to achieve optimal treat-
ment fidelity. This included strategies employed both prior
to, and during, the treatment period to effectively imple-
ment in-home tES and approaches to monitor use of
in-home tES during the treatment period to ensure it is
both effective and safe. Where reported, adverse events,
protocol adherence and participant perspectives were also
synthesised using a narrative approach and discussed with




A total of 957 related studies were identified, with 65
duplicates removed, leaving 892 studies for title and ab-
stract screening. Following title and abstract screening,
48 studies remained and full text articles of those studies
were screened for eligibility. Out of these 48 studies, 28
were discarded as 11 studies were found to have the
wrong study design (three review articles, one book
chapter, six methodological or guideline papers and one
protocol paper) and one had the wrong study popula-
tion. The other 16 studies were considered duplicates as
they were conference abstracts related to full text studies
already included in the review. Thus, in total, this sys-
tematic review included 20 studies. One additional study
[37] was excluded from this review as it was identified
through communication with the author that the data
came from a trial that was already included within the
review [38]. As B Dobbs, N Pawlak, M Biagioni, S Agar-
wal, M Shaw, G Pilloni, M Bikson, A Datta and L Char-
vet [38] reported all outcomes of interest to this review,
it was decided that data would be extracted from this
study. As a result, there were 19 studies identified with
data from unique trials (Fig. 1).
Description of included studies
All 19 studies are summarised in Table 1. Although the
inclusion criteria for this review included several varia-
tions of tES, all identified studies used tDCS as the form
of brain stimulation, with none using tACS or tRNS.
The studies were relatively recent, all being published
within the past 5 years (2013–2018), while 84% were
published within the last 2 years (2016–2018). Of the in-
cluded studies, five were identified as randomised con-
trolled trials [39–43], two randomised cross-over trials
[44, 45], two observational studies [46, 47], ten case
series [38, 48–56].Risk of bias in included studies
Review of internal validity using the Cochrane risk of
bias assessment tool in seven domains is summarised
in Fig. 2. In keeping with the low level of research
design, which likely reflects the preliminary nature of
current work, the majority of studies had a high risk
of bias. Few studies (26.3%) demonstrated low risk for
random sequence generation [39–41, 43, 45], alloca-
tion concealment (15.8%) [40, 41, 45], blinding of
personnel and participants (42.1%) [39–46] and blind-
ing of outcome assessments (26.3%) [40, 41, 43–45].
However, a large proportion of studies (94.7%) dem-
onstrated low risk of bias for incomplete outcome
data, with only one study identified as high risk of
bias due to an increased number of participants who
withdrew from the study [44]. Selective reporting was
generally (68.4%) identified as an unclear level of bias
[40, 42–44, 46–49, 51–55], with two studies identified
as high risk of bias [38, 39], and one as low risk of
bias [41] in this category. One study was identified as
high risk of bias under the domain of other sources
of bias due to substantial variation in duration and
intensity of stimulation based on response to treat-
ment [52]. However, we note that the overall purpose
of this study was different compared to all other in-
cluded studies as it was a maintenance program for
symptoms of schizophrenia.Participants’ characteristics and stimulation protocols
There were various patient populations included in this
review for in-home tES (Table 1). Four studies were per-
formed with people who had Multiple Sclerosis (MS)
[40, 47, 48, 54], two with Parkinson’s disease (PD) [38,
43] and two with stroke [41, 56]. Other populations in-
cluded tinnitus [46], dementia [42], minimally conscious
state [45], Mal de Debarquement syndrome [39], trigem-
inal neuralgia [44], neuropathic pain [55], depression
[49], multimodal hallucinatory perceptions [53], schizo-
phrenia [52], various neurological pain conditions [51]
and a case series of four chronically ill patients which in-
cluded myasthenia gravis, depression, chronic pain and
stroke [50].
In-home tES treatment was provided over a wide
range of different durations from 4 [42] to 400 sessions
[53], with the most common approach to apply in-home
tES for 10–20 sessions [38–40, 43–51]. One study did
not report the number of treatment sessions which
ranged from once to twice daily over a period of 3 years
[52]. The duration for each treatment was 20–30min for
all included studies, with the majority applying stimula-
tion at 1-2 mA. Only one study exceeded 2mA, with
stimulation intensity increased up to 3 mA to control
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Fig. 2 Cochrane risk of bias tool was used to assess quality of included studies
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home brain stimulation
Across the 19 included studies, there were a range of
strategies used both prior to, and during, the treatment
period to implement in-home tES (Table 2). The most
common approach was to conduct training sessions
prior to beginning in-home tES. This frequently included
practicing the placement and positioning of electrodes
on the scalp, sponge preparation, starting the stimulator,
troubleshooting common problems and provision of
training videos [39, 46, 53]. Furthermore, several studies
extended the training sessions to include a caregiver, or
support person, who was able to assist during the home
treatment phase. For some studies, the assistance of a
caregiver, or support person, was a requirement for all
participants [44, 48, 50, 55], and others specifying it only
for those participants with higher disability [38, 40, 47].
During delivery of in-home tES, several monitoring
approaches were identified as strategies to achieve opti-
mal treatment fidelity (Table 3). The most common
treatment monitoring approach was to use videoconfer-
encing to observe, in real time, the in-home treatment
being conducted by the patients or their caregivers [38–
40, 43, 47–50, 54–56]. This provided researchers oppor-
tunity to visualise tES set-up, correct electrode place-
ment and troubleshoot issues that arose. Monitoring
in-home stimulation in this manner may also assist with
compliance with the treatment protocol. Five studies
which utilised videoconferencing as a method tomonitor in-home tES also used a remote desktop access
approach for each treatment [38, 43, 47, 48, 50, 56]. This
allowed research staff to have strict dose control for the
delivery of tES and remotely solve any technology-based
issues that arose. Four studies used passive (not in real
time) monitoring approaches which included recording
use of tES through websites such as Survey Monkey [39]
or with self-report treatment diaries [44–46].
Protocol compliance
Table 3 shows that most studies reported a high level of
compliance with the in-home tES treatment program
which was defined as the percentage of correctly com-
pleted stimulation sessions relative to the total number of
intended sessions. Seven studies had 100% compliance,
with three additional studies having 95% compliance or
greater and a further three studies reporting 90–95% com-
pliance. These results suggest that it is possible to imple-
ment an in-home tES study and obtain an excellent level
of compliance. An observation from this review is that
studies which provided regular and repeated real-time vid-
eoconferencing to monitor each in-home treatment ses-
sion achieved compliance levels of 93% or greater [38–40,
43, 47, 48, 50, 54–56]. One study delivered in-home tES
with research staff attending a participant’s home as op-
posed to the study participant performing stimulation in-
dependently, achieving 100% compliance [41].
The studies which did not use real-time videoconferenc-
ing to monitor each in-home treatment session reported
Table 2 Strategies identified to implement in-home tES













Kasschau 2016 ✓ ✓ ✓ ✓ ✓
Riggs 2018 ✓ ✓ ✓ ✓ ✓
Dobbs 2018 ✓ ✓ ✓ ✓
Sharma 2018 ✓ ✓ ✓ ✓
Van de Winckel 2018 ✓ ✓ ✓ ✓
Charvet 2017a ✓ ✓ ✓ ✓
Charvet 2017b ✓ ✓ ✓ ?
Carvalho 2018 ✓ ✓
Hagenacker 2014 ✓ ✓
Cha 2016 ✓ ✓









Note; Andrade 2013, Andre 2016 and Clayton 2018 did not report any strategy to implement in-home tES
✓; Reported as a strategy to implement in-home tES
?; Charvet 2017b reported each participant was provided a laptop that enabled connection to a study technician. It is not stated whether this included remote
computer access
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compliance levels (see Table 3). These strategies included
a single real-time videoconference call for the first
in-home treatment session only, daily phone calls and
emails and self-reported treatment diaries [44–46, 49]. Al-
though there may be some indication that strategies to
monitor in-home tES may influence protocol compliance,
there are likely to be additional factors which contribute
to this outcome. For example, it is important to acknow-
ledge that protocol compliance may be affected by the
duration of the experiment with high levels of compliance
likely to be more difficult to achieve with more home
stimulation sessions. Within this review, those studies
with relatively higher levels of protocol compliance gener-
ally conducted 5–20 sessions, while those with relatively
lower levels of compliance conduced 10–20 sessions.
As opposed to monitoring strategies, where video-
conferencing appears to be a factor that may enable
high levels of protocol compliance, there did not ap-
pear to be any association between a particular strat-
egy to implement in-home tES and protocol
compliance (Table 2). For example, some of the stud-
ies which reported relatively high levels of compliance
used various strategies to implement in-home tESsuch as training sessions for participants and care-
givers [38, 43, 47, 48, 50, 55, 56], customised head-
bands [38–40, 43, 47, 48, 50, 56] and remote
computer access [38, 43, 47, 48, 50, 56], while others
did not report any strategies [54]. However, it may be
that use of multiple strategies is best. Of the studies
which used three or more strategies to prepare the
participant and deliver the in-home tES program, re-
ported compliance levels were between 93 and 100%
[38, 40, 43, 47, 48, 50, 56]. For studies which used
two strategies or less, compliance levels appeared
more variable and were as low as 76% [44].
Adverse events
Eighteen studies reported outcomes for adverse events
(Table 4). The most common event was tingling sensa-
tions during the stimulation, which was reported in 12
studies [38–41, 43, 44, 46, 48, 52, 54–56]. Other com-
mon adverse events were itching or skin irritation, burn-
ing sensation, head pain, difficulties in concentrating,
blurred vision, facial muscle twitching and changes in
mood. There did not appear to be any association be-
tween adverse events and strategies to implement or
monitor in-home tES. One study reported occurrence of
Table 3 Monitoring approaches and protocol compliance of
the studies
Study Monitoring approaches Compliance
Mortenson
2016
Direct in-person monitoring 100%
Clayton 2018 Real-time videoconferencing 100%




Remote administration of tDCS
delivery
100%
Riggs 2018 Real-time videoconferencing
Remote administration of tDCS
delivery
100%
Dobbs 2018 Real-time videoconferencing
Remote administration of tDCS
delivery
100%
Sharma 2018 Real-time videoconferencing
Remote administration of tDCS
delivery
100%
Charvet 2017a Real-time videoconferencing
Remote administration of tDCS
delivery
> 96%
Cha 2016 Real-time videoconferencing
Daily online-tracking and reporting
system
96%
Kasschau 2016 Real-time videoconferencing
Remote administration of tDCS
delivery
96%
Charvet 2017b1 Real-time videoconferencing
Remote administration of tDCS
delivery
93%
Hyvarinen 2016 Daily self-report treatment diary 91%
Loo 2017 Initial sessions real-time
videoconferencing
Daily phone or email contact
90%





Daily self-report treatment diary 76%
1, data only reported for study two
Table 4 Reported adverse events for in-home tES
Adverse Events
Andrade 2013 Tingling sensation at the electrode site
Andre 2016 No adverse events occurred
Carvalho 2018 Minor and transient scalp burn, tingling and skin
redness
Cha 2016 Tingling, itching, redness, headache, tiredness,
confusion, nausea.
Charvet 2017a Not stated
Charvet 2017b1 Pain > 6/10 (n = 2). Tingling (43%), itching (21%),
burning sensation (23%), head pain or pressure (2%),
dizziness (< 1%), difficulty concentrating (4%), blurred
vision (<1%) and facial muscle twitch (<1%).
Clayton 2018 Minimal and transient tingling and itchiness at the site
of electrodes
Dobbs 2018 Tingling (43%), burning (29%), head pain (8%), itching
(8%), headache (6%), difficulty concentrating (1%)
Hagenacker
2014
Slight itching or tingling
Hyvarinen 2016 Tinnitus loudness and annoyance (5%), skin burn (2%);
irritation (2%), mood changes (2%), tingling sensation
(5%), uncomfortable sensation (47%), poor sleep (7%)
Kasschau 2016 Tingling (60%), itching (24%), burning (30%), headache
(3%), nausea (3%), head pain (3%), dizziness (<1%),
difficulty concentrating (1%), blurred vision (<1%),
forgetfulness (<1%).
Loo 2017 No significant adverse events occurred
Martens 2018 Skin redness (37%), sleepiness (11%), seizure (4%)*
Mortenson 2016 Mild itching, tingling, burning sensation, headache
and sleepiness
Riggs 2018 No adverse events occurred
Schwippel 2017 No adverse events occurred
Sharma 2018 Tingling (20%), itching (6.5%), burning (8.3%), dizziness
(0.4%), headache (2.2%), sleepiness (0.4%, nausea
(0.4%)
Treister 2015 No serious adverse events occurred
Van de Winckel
2018
Mild tingling at electrode site at beginning of
treatment (83%)
1, data only reported for study two
*Unlikely related to stimulation as it occurred in the sham group in a
participant with history of epilepsy
Sandran et al. Journal of NeuroEngineering and Rehabilitation           (2019) 16:58 Page 8 of 13a seizure, however the authors suggest this was not asso-
ciated with stimulation as the participant was receiving a
sham condition (no stimulation) and had a history of
epilepsy [45]. Excluding the occurrence of this seizure
which did not appear to be associated with delivery of
tDCS, none of the reported adverse events would be
considered severe or requiring medical attention.
Participants’ satisfaction
Participants’ satisfaction towards the treatment was only
reported by six studies [39, 46, 48, 50, 55, 56]. For five
studies where real-time monitoring was provided, but a
range of different strategies were employed to prepare
participants for home stimulation, authors reported that
participants generally had positive experiences withusing in-home tES [39, 48, 50, 55, 56]. These studies
were performed in various clinical populations that in-
cluded neuropathic pain, Mal de Debarquement Syn-
drome, stroke, depression, myasthenia gravis, chronic
pain and Multiple Sclerosis. Themes that emerged in-
cluded users reporting that there were no difficulties in
the treatment set-up, being comfortable with the stimu-
lation device, being satisfied with the overall experience
and expressing a desire to continue this home-based
treatment after the study [48, 50, 55, 56] with purchase
of their own stimulator [39]. However, some participants
with Mal de Debarquement Syndrome, a condition char-
acterised by feelings of rocking or swaying after exposure
Sandran et al. Journal of NeuroEngineering and Rehabilitation           (2019) 16:58 Page 9 of 13to motion, reported feeling uncomfortable applying the
stimulation independently and reported frustration set-
ting up the device and achieving appropriate levels of
impedance to start stimulation [39]. The fourth study re-
ported the perspectives of people with tinnitus who used
in-home tES and were provided with self-reported treat-
ment diaries to monitor stimulation [46]. The authors
reported six out of 35 participants felt it was difficult to
apply stimulation despite being providing with a one-day
training session and instruction notes.
Registered clinical trials
The search of trial registries (clinicaltrials.gov, anzctr.
org.au and who.int/ictrp/en/) identified ten clinical stud-
ies which are currently ongoing or completed, but not
yet published (Table 5). These studies implemented
in-home tES in various neurological and psychiatric con-
ditions. Four studies stated that videoconferencing (or
telemedicine) will form part of the monitoring strategy
to implement in-home tES. Few studies have identified
that they will be reporting on the occurrence of adverse
events, protocol compliance or patients’ perspective.
However, it is worth noting that limited information is
required to be provided in clinical trial registries.Table 5 Clinical trials which are currently investigating in-home tES




















training (20 sessions, 4
weeks)




tDCS (20 sessions, 4
weeks)
ISRCTN56839387 Completed Chronic Pain tDCS (5 sessions)
ACTRN12618000443291 Recruiting Stroke tDCS and arm exercise
(14 sessions, 2 weeks)
ACTRN12615000592549 Recruiting Tourette
Syndrome
tDCS (18 sessions, 9
weeks)
tDCS transcranial direct current stimulation
Tick = reported in trial registry
? = not clearly reported in trial registryDiscussion
It is clear that in-home tES is an area of current research
interest. Of the studies identified in this review, the ma-
jority were published within the last few years. Generally,
these studies have been conducted in relatively small
samples of patients, suggesting that current work is
mostly around testing feasibility, safety and tolerability
of this approach. As a result, many studies were found
to have high levels of bias due to the less rigorous re-
search designs employed. Nevertheless, this review iden-
tified a number of key findings from current evidence
which will inform future in-home tES research and clin-
ical practice. First, several different strategies were iden-
tified to implement and monitor in-home tES. The
requirement to monitor stimulation appears to be a crit-
ical component to the successful implementation of
in-home tES. Second, studies that employ real-time vid-
eoconferencing as a strategy to monitor in-home tES
seemed to be associated with increased compliance with
stimulation protocols and could possibly contribute to
greater patient satisfaction with this form of treatment.
Finally, from the available evidence, there does not ap-
pear to be any indication of severe adverse events associ-
ated with stimulation, suggesting that in-home tES isin neurological or psychiatric conditions
Strategies to implement or
monitor in-home tES





Real-time videoconferencing ? ? ?
Real-time videoconferencing




Caregiver will be trained in tDCS.
No monitoring strategy reported
? ? ?
Monitoring strategy not reported ? ? ?
Real-time videoconferencing ? ? ?
Not reported ? ? ?
Monitoring strategy not reported ? ? ?
Not reported ? ? ?
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advantages of delivering tES within a participant’s home,
we suggest future studies continue to explore this
approach.
The primary aim of this review was to identify ap-
proaches to implement and monitor in-home tES and
achieve optimal treatment fidelity. We were particularly
motivated to investigate this research question because
in-home tES is likely to require significant consideration
to ensure stimulation is performed correctly and in ac-
cordance with the treatment program, while maintaining
patient safety. Therefore, strategies to implement and
monitor in-home tES will be essential to ensure correct
set-up and electrode preparation prior to stimulation, as
well as to troubleshoot any issues that arise. It is clear
from the available evidence that several approaches have
been employed and these are likely to be critical aspects
of future work for in-home tES. It is of particular note
that studies which used real-time videoconferencing to
monitor stimulation remotely were associated with
higher levels of compliance (93–100%) with the in-home
tES program [38–40, 43, 47, 48, 50, 54–56]. These are
impressive levels of protocol compliance that are com-
parable to, or even greater, than that reported in previ-
ous clinical trials or research studies [9, 57, 58]. It
should be noted that several of these studies did follow
similar methodology as they followed an earlier guide-
lines paper that proposed a comprehensive approach to
implement in-home tES [34]. However, despite similarity
in their methodology, it is interesting to note that higher
levels of compliance were observed across several differ-
ent clinical populations and unique datasets. It is per-
haps not surprising this approach resulted in greater
compliance with the treatment protocol. Regular contact
and viewing each treatment session in real-time likely ensured
that technical or set-up difficulties were appropriately dealt
with in an efficient and timely manner, preventing these chal-
lenges from affecting treatment compliance. There is also
likely to be opportunity for research staff to motivate and en-
courage participants to continue with the treatment protocol
where regular videoconferencing sessions are performed.
These positive outcomes are supported by various telehealth
studies where videoconferencing has been used to monitor
treatments undertaken remotely in a patient’s home [59, 60].
However, in contrast to monitoring with real-time videocon-
ferencing, we note that compliance with treatment protocols
did not appear to reflect any particular strategy employed to
prepare the participant for the in-home tES and deliver the
program such as training participants or caregivers in the use
of in-home tES, or the use of customised headbands. How-
ever, this in no way should undermine the importance of
training sessions or additional approaches to prepare partici-
pants for performing in-home tES. Indeed, there is some indi-
cation that use of multiple strategies (at least three differentapproaches) to prepare the participant and deliver the
in-home tES program may be associated with greater proto-
col compliance. However, this requires further investigation.
Therefore, at this stage we suggest a multifaceted approach
combining several of the identified strategies to prepare and
train the participant to use tES in their own home along with
real-time videoconferencing to monitor stimulation may be
best. Future work should continue to explore approaches to
ensure delivery of in-home tES is an acceptable, easy and safe.
Aside from videoconferencing, there were several
other methods that have been used to monitor in-home
tES treatments. For example, participants were required
to self-report treatments using either treatment diaries
[44–46] or online tracking systems [39]. While
self-reported approaches do provide a record of in-home
tES use, the accuracy of this approach relies upon regu-
lar reporting and accurate recall. As self-reported
approaches do not obtain real-time information relating
to in-home tES sessions, research staff are unable to
monitor treatment sessions. This may prevent the ability
to ensure correct electrode preparation, set-up and start-
ing of the stimulator. These difficulties faced during the
treatment phase by the study participants might contrib-
ute to the lower compliance. One interesting observation
is that the use of real-time videoconferencing for moni-
toring in-home tES may have to be ongoing, and regular,
to help achieve best protocol compliance. This observa-
tion is supported by CK Loo, A Alonzo and J Fong [49],
where compliance was reported as 90% with a protocol
which included a videoconference performed for the ini-
tial in-home tES session only, with the remaining ses-
sions monitored through phone and email contact.
There is also some indication that regular videocon-
ferencing sessions may contribute to greater patient
satisfaction with using in-home tES. Few studies,
which did use videoconferencing to monitor in-home
tES, reported that study participants were able to
set-up the stimulator and begin treatment without
difficulty and were interested in continuing treatment
with in-home tES [39, 48, 50, 55, 56]. However, pa-
tient perspectives were not commonly reported by the
studies included in this review and this is an area for
future investigation. Ensuring higher levels of satisfac-
tion may assist with improving compliance with home
treatment programs and may help facilitates clinical
translation of this approach.
While a concern regarding in-home tES may be
greater risk of injury from stimulation, results from this
review suggest that no severe adverse events associated
with receiving stimulation occurred during in-home tES
and that any reported adverse events were akin to those
reported for tES trials performed in clinics or research
facilities [26, 61]. Common adverse events that were re-
ported included tingling, burning and itching sensations
Sandran et al. Journal of NeuroEngineering and Rehabilitation           (2019) 16:58 Page 11 of 13especially at the electrode placement site. One study did
report that participants experienced poor sleep and
mood changes [46]. It is not clear why these adverse
events occurred in this study involving stimulation ap-
plied to either the auditory cortex or frontal cortex in
people with tinnitus. However, we do note that this
study used a passive monitoring approach of
self-reported treatment diaries. This may have limited
the ability of the research team to track the progression
of these symptoms at each session and discuss ap-
proaches to manage, or prevent, their occurrence. Fur-
thermore, we note that one seizure was reported but
was unlikely related to the home tES as it occurred to a
participant receiving sham stimulation who had a history
of epilepsy. While there does not appear to be a relation-
ship between monitoring strategies for in-home tES and
the occurrence of adverse events, we suggest that
real-time monitoring approaches, such as videoconfer-
encing, should be used to ensure patient safety and limit
potential for adverse events to occur.
A limitation of the current study is that it does not ac-
count for the various patient groups that were included. It
is likely that different pathology and patient characteristics
could influence treatment compliance and satisfaction
with in-home tES. As the current literature around
in-home tES continues to grow, it is recommended future
studies investigate how different patient groups respond
and accept in-home tES. It may be that specific monitor-
ing approaches or strategies to implement in-home tES
are required for different patient populations to ensure
high levels of treatment compliance and satisfaction are
achieved.
Conclusion
Although in-home tES is a relatively new area of re-
search, current evidence indicates that this is a feasible,
acceptable and safe approach to deliver non-invasive
brain stimulation treatment for a range of neurological
and psychiatric conditions. This review indicates that the
use of videoconferencing to monitor in-home tES can
result in excellent levels of treatment fidelity and poten-
tially greater participant satisfaction. While there are dif-
ferent approaches to implement and monitor in-home
tES, we suggest real-time monitoring through videocon-
ferencing should be included as one of these strategies
in future studies. The area of in-home tES research is
rapidly developing, driven in part by the ability to deliver
consecutive stimulation sessions without overburdening
people who are unwell by requiring that they travel fre-
quently to receive treatment. We suggest future studies
continue to explore patient groups which may benefit
from this treatment approach and continue to monitor
critical aspects of protocol compliance, adverse events
and participant satisfaction. This information will helpshape delivery of in-home tES to ensure that best pos-
sible services are provided.
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